A Deep Dive into the FDA Approval of NDA 215244 (s000): What We Know, What It Means, and What Comes Next
Introduction The issuance of label 215244s000 marks the formal U.S. FDA approval of a new therapeutic agent (or new indication) under NDA 215,244. While publicly available summaries are scarce, the full prescribing label document offers a wealth of technical information that can be unpacked to understand the drug’s mechanism, safety/efficacy profile, clinical trial evidence, potential […]
Rethinking Acetaminophen Use During Pregnancy: What the Latest FDA Announcement Means for Expectant Mothers
IntroductionAcetaminophen (also commonly known by brand names like Tylenol) has long been regarded as the go-to over-the-counter medication for pain relief and fever reduction during pregnancy. It is often considered safer than alternatives such as ibuprofen or aspirin, which carry known fetal risks. However, on September 22, 2025, the U.S. Food and Drug Administration (FDA) […]
RYBREVANT (amivantamab-vmjw) 2025 Label: What Changed, Why It Matters, and How to Apply It in Practice
Bottom line: In early 2025 the RYBREVANT label tightened safety language (notably infusion-related reactions, anaphylaxis placement, and venous thromboembolism management with lazertinib) and clarified dosing/administration details. Later in 2025, FDA accepted a supplement to update overall survival results from MARIPOSA, which will flow into Clinical Studies once the updated PI posts. Together, these moves round […]
EPYSQLI® (Eculizumab-aagh) — A Landmark Biosimilar in Rare Disease Treatment
Introduction Samsung Bioepis’ EPYSQLI® (eculizumab-aagh) has earned FDA approval as a biosimilar to Soliris® (eculizumab). Approved on July 19, 2024, EPYSQLI offers a more affordable alternative for treating debilitating rare diseases.FDA Access DataSamsung BioepisU.S. Pharmacist Indications EPYSQLI is indicated for: Efficacy & Clinical Performance EPYSQLI matches the reference biologic in both efficacy and safety: Cost […]
Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products
In March 2022, the U.S. Food and Drug Administration (FDA) released a draft guidance titled “Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products.” This document provides detailed recommendations for industry and academic sponsors involved in the development of CAR T cell therapies, aiming to streamline the development process and ensure the […]
Technical Specifications for Submitting Clinical Trial Data Sets for Treatment of Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
The U.S. Food and Drug Administration (FDA) plays a crucial role in ensuring drug safety and effectiveness. One of its key regulatory tools is the Risk Evaluation and Mitigation Strategies (REMS) program, which aims to manage known or potential serious risks associated with certain medications. The FDA’s guidance document, titled “Risk Evaluation and Mitigation Strategies: […]
Pharmacovigilance registration process timeline for Shudarsana Company
Institutional Review Board (IRB) Written Procedures | Shudarsana Company
FDA Issues New Guidance on IRB Written Procedures: Key Insights for Institutions The U.S. Food and Drug Administration (FDA) has released updated guidance on Institutional Review Board (IRB) Written Procedures in February 2025 to align with evolving human subject research regulations. This new guidance reflects the FDA’s commitment to harmonizing regulations with the Department of […]
Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) | Shudarsana Company
Introduction In January 2025, the U.S. Food and Drug Administration (FDA) released crucial guidance titled “Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).” This guidance addresses significant health risks linked to HCT/Ps, including outbreaks of Mycobacterium tuberculosis (Mtb) infections caused […]